SR142948A is a Potent Antagonist of the Cardiovascular Effects of Neurotensin

    loading  Checking for direct PDF access through Ovid



The novel compound SR142948A was compared with SR48692 as an antagonist of neurotensin-induced cardiovascular effects both in vitro and in vivo. SR142948A inhibited [125I]-neurotensin binding [median inhibitory concentration (IC50) = 0.24 ± 0.01 nM], neurotensin-induced cytosolic free Ca2+ increase (IC50 = 19 ± 6 nM), and prostacyclin production in human umbilical vein endothelial cells (IC50 = 17 ± 3 nM) at much lower concentrations than did SR48692 (respective IC50 values, 14 ± 5, 41 ± 16, and 86 ± 16 nM). Oral administration of SR142948A (10 μg/kg) resulted in significant inhibition of neurotensin-induced blood pressure changes, whereas SR48692 was active only at 10-fold higher doses. Furthermore, SR142948A administered i.v. in μg/kg quantities in the rat was as active as mg/kg doses of SR48692 on neurotensin-induced increase in hematocrit. SR142948A injected intradermally also significantly inhibited neurotensin-induced plasma extravasation at concentrations as low as 10 pmol/site, whereas 1,000 pmol/site of SR48692 were necessary to reach a significant inhibition. These data show that SR142948A is a novel, extremely potent antagonist of neurotensin-induced cardiovascular responses both in vitro and in vivo. SR142948A and SR48692 constitute a pair of nonpeptide neurotensin antagonists of different potency, which may be used to probe for the implication of neurotensin receptors in physiologic or pathologic phenomena.

Related Topics

    loading  Loading Related Articles